Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2003
09/10/2003EP1035835B1 Long acting injectable formulations containing hydrogenated castor oil
09/10/2003EP1023052B1 Medicament excipient particles for tissue-specific application of a medicament
09/10/2003EP1007632A4 Isolation of bone and cartilage precursor cells
09/10/2003EP0981377B1 cOMPLEXES OF THE LHRH-ANTAGONIST CETRORELIX WITH POLY-AMINO ACIDS AND METHOD FOR THEIR PRODUCTION
09/10/2003EP0977553B1 Throat soothing compositions
09/10/2003EP0973501B1 Aqueous suspension for nasal administration of loteprednol
09/10/2003EP0946202B1 Contrast agents
09/10/2003EP0921806B1 Mannose-6-phosphate composition and its use in treating fibrotic disorders
09/10/2003EP0906122B1 Activated linkers and methods for making and purifying the same
09/10/2003EP0873139B1 Biotinylated antibodies with reduced net positive charge and toxin, drug or chelate
09/10/2003EP0783299B1 Compounds and compositions for delivering active agents
09/10/2003EP0769951B1 Long-acting oxytetracycline composition
09/10/2003EP0752890B1 Segmented chelating polymers as imaging and therapeutic agents
09/10/2003EP0689843B1 Composition containing soluble thrombomodulins
09/10/2003EP0686025B1 Titanium dioxide dispersions, cosmetic compositions and methods for using the same
09/10/2003CN1441820A Method for preparing functionalised poly alkylenimides, composition containing same and uses thereof
09/10/2003CN1441808A Chemokine receptor modulators, production and use
09/10/2003CN1441770A Modified forms of pharmacologically active agents and uses therefor
09/10/2003CN1441704A Medium milling
09/10/2003CN1441680A Cyclodextrin containing glycopeptide antibiotic pharmaceutical compositions
09/10/2003CN1441679A Compositions containing therapentically active components having enhanced solubility
09/10/2003CN1441678A Compounds with sulphonamide group and pharmaceutical compositions containing these compounds
09/10/2003CN1441676A Method of treatment using ligand-immunogen conjugates
09/10/2003CN1441674A Diphosphonate solutions
09/10/2003CN1441672A Methods for treatment of inflammatory diseases
09/10/2003CN1441669A Method for formulating healthcare products with enhanced stability
09/10/2003CN1441668A Compositions and methods to improve oral absorption of antimicrobial agents
09/10/2003CN1441667A Pharmaceutical compositions
09/10/2003CN1441666A Macromolecular drug complexes and compositions containing same
09/10/2003CN1441664A Synergistic antiplaque/antigivitis oral composition
09/10/2003CN1440816A Improvement for diagnosis and/or therapeutic agnet and its relative improvement
09/10/2003CN1440745A Fluoxetine medicinal preparation
09/10/2003CN1120724C Stable liquid composition of gamma interferon
09/10/2003CN1120707C Ligands to enhance cellular uptake of biomolecules
09/09/2003US6617456 Camptothecin derivatives
09/09/2003US6617356 Comprising a stable suspension of silicon dioxide in a number selected from the group consisting of food grade vegetable oils and mineral oils, and the carrier being in the form of pourable gel
09/09/2003US6617349 Blends of isoflavones and flavones
09/09/2003US6617338 Condensation of omeprazole, lansoprazole or pantoprazole with an addition copolymer having acrylonitrile, acrylic ester or aromatic olefin monomers, to form the polymer conjugate; improved bioavailability
09/09/2003US6617328 Sustained release ranolazine formulations
09/09/2003US6617321 2-methyl-thieno-benzodiazepine formulation
09/09/2003US6617314 Injectable formulations of avermectins and milbemycins
09/09/2003US6617306 Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond.
09/09/2003US6617305 Stable aqueous dispersion of nutrients
09/09/2003US6617151 Method of closing a cell containment device with a wet seal
09/09/2003US6616948 Generating prferential macromolecule carbohydrate; obtain solid carbohydrate, wash, hydrolyze, recover preferential carbohydrate
09/09/2003US6616946 Triblock copolymer hollow particles for agent delivery by permeability change
09/09/2003US6616944 Self-assembling colloidal carriers for protein delivery
09/09/2003US6616941 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
09/09/2003US6616932 Liquid pharmaceutical for oral delivery
09/09/2003US6616931 Containing sugar; phosphate; carboxylate; recombinant human serum albumin or a nonionic surfactant
09/09/2003US6616930 Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
09/09/2003US6616913 Composition and method for treatment of otitis media
09/09/2003US6616591 Radioactive compositions and methods of use thereof
09/09/2003CA2239498C Bioartificial devices and cellular matrices therefor
09/09/2003CA2175472C Propylene glycol stearate vesicles
09/09/2003CA2101648C Polysaccharide-protein conjugates
09/09/2003CA2057291C A stable pharmaceutical composition of human calcitonin
09/04/2003WO2003072754A2 Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
09/04/2003WO2003072735A2 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
09/04/2003WO2003072711A2 Method of using modified oligonucleotides for hepatic delivery
09/04/2003WO2003072705A2 Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
09/04/2003WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/04/2003WO2003072637A1 Carbohydrate-modified polymers, compositions and uses related thereto
09/04/2003WO2003072631A1 Biodegradable polymeric material for biomedical applications
09/04/2003WO2003072542A2 Interfacial biomaterials
09/04/2003WO2003072535A2 Substituted hydroxyethylamines
09/04/2003WO2003072196A1 Lower esophagus tissue modifier
09/04/2003WO2003072195A2 Method for administering glp-1 molecules
09/04/2003WO2003072143A1 Compositions for delivery of therapeutics and other materials, and methods of making and using the same
09/04/2003WO2003072141A1 Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
09/04/2003WO2003072140A1 Compression-molded preparions with quick-disintegration properties
09/04/2003WO2003072139A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
09/04/2003WO2003072123A1 Stabilized albumin preparaions
09/04/2003WO2003072113A1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
09/04/2003WO2003072112A1 'long'-'acting' injectable parasiticidal composition
09/04/2003WO2003072108A1 Novel crystalline forms of the anti-cancer compound zd1839
09/04/2003WO2003072096A1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
09/04/2003WO2003072094A1 Ambroxol for treating painful conditions in the mouth and pharyngeal cavity
09/04/2003WO2003072091A1 Therapeutic methods for acute myeloid leukemia
09/04/2003WO2003072089A1 Controlled release dosage forms
09/04/2003WO2003072087A1 Pharmaceutical dosage form and method for the production thereof
09/04/2003WO2003072086A1 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core
09/04/2003WO2003072084A1 Fast disintegrating tablets
09/04/2003WO2003072083A2 Melt extrusion consisting of salts of active ingredients
09/04/2003WO2003072082A1 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
09/04/2003WO2003072081A1 Ophthalmic formulation with gum system
09/04/2003WO2003072071A1 Topical dapsone for the treatment of acne
09/04/2003WO2003072060A2 Polypeptide formulation
09/04/2003WO2003072058A2 Dna-binding polyamide drug conjugates
09/04/2003WO2003072047A2 Idothyronine compositions
09/04/2003WO2003072046A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
09/04/2003WO2003072025A2 Modified release formulations of at least one form of tramadol
09/04/2003WO2003072022A2 Oral trimethobenzamide formulations and methods
09/04/2003WO2003072021A2 Oral pediatric trimethobenzamide formulations and methods
09/04/2003WO2003072020A2 Therapeutical polyanhydride compounds for drug delivery
09/04/2003WO2003072017A2 Macromolecular conjugates and processes for preparing same
09/04/2003WO2003072016A2 Pharmaceutical compositions in particulate form
09/04/2003WO2003063840A3 Transmucosal delivery of proton pump inhibitors
09/04/2003WO2003057006A3 Use of antibodies against the muc18 antigen
09/04/2003WO2003045306A3 Phenoxy amine compounds and compositions for delivering active agents
1 ... 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 ... 1712